“<a href="http://www.world-today-news.com/crispr-gene-editing-and-long-acting-art-a-dual-therapy-strategy-for-hiv-elimination-in-mice/" title="CRISPR Gene Editing and Long-Acting ART: A Dual Therapy Strategy for HIV Elimination in Mice”>Long-acting antiretroviral therapy is a promising option in the management of HIV, as it offers significant advantages for patients’ quality of life. It is a long-acting therapy, approximately 2 months, and this is a big innovation, but we are only at the beginning of this revolution because drugs are being studied that can be administered every 6 months perhaps with subcutaneous implants.” Thus Paolo Maggi, associate professor at the University of Campania Luigi Vanvitelli, in his speech on the occasion of the conference ‘Infectious diseases in the setting of the immunocompromised patient’, underway in Naples with a focus on HIV, a pathology which in Campania the numbers of new cases are stable, but there are also limits to access to new and innovative treatments such as long acting.
“Until 10-15 years ago, HIV patients took up to 10-15 tablets a day. With enormous efforts we arrived at the administration of one tablet and today, thanks to long acting therapy, the patient has much longer coverage with notable advantages”, added Maggi who also underlined another aspect: “In Campania, access to this treatment is limited. These drugs can only be provided through outpatient services. Campania is one of the few regions that has patient management with HIV in day hospital and if they are followed in day hospital they cannot have this drug. We are saying no to many, too many patients, and the probability that they will go elsewhere to be treated is certainly high because people with HIV are very different years ago: they are educated, informed people, they know that this type of therapy exists, they request it and it is a problem not to be able to satisfy them. It is essential – he concluded – that the health authorities and local organizations work to improve access to it therapies, ensuring that all patients can benefit from these innovations.”
